Zobrazeno 1 - 10
of 306
pro vyhledávání: '"Robert S Svatek"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5080ab3da4ac47818fbbb9c067ebe123
Autor:
Yilun Deng, Aravind Kancharla, Myrna Garcia, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Tyler J Curiel, Robert S Svatek, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Chenghao Zhang, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in
Externí odkaz:
https://doaj.org/article/2a231be16e8747f5b3befb1e7bde6cde
Autor:
Niannian Ji, Neelam Mukherjee, Tyler J Curiel, Ryan M Reyes, Jonathan Gelfond, Martin Javors, Joshua J. Meeks, David J McConkey, Zhen-Ju Shu, Chethan Ramamurthy, Ryan Dennett, Robert S Svatek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the
Externí odkaz:
https://doaj.org/article/8727334813974223b8ab1c8584e1818e
Autor:
Ryan M Reyes, Chenghao Zhang, Yilun Deng, Niannian Ji, Neelam Mukherjee, Alvaro S Padron, Curtis A Clark, Robert S Svatek, Tyler J Curiel
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Bladder cancer (BC) and melanoma are amenable to immune checkpoint blockade (ICB) therapy, yet most patients with advanced/metastatic disease do not respond. CD122-targeted interleukin (IL)-2 can improve ICB efficacy, but mechanisms are unclear. We t
Externí odkaz:
https://doaj.org/article/6f57b3a6ecf3451ead7b6bb61c301abc
Autor:
Neelam Mukherjee, Niannian Ji, Xi Tan, Chun‐Liang Chen, Onika D. V. Noel, Maria Rodriguez‐Padron, Chun‐Lin Lin, David G. Alonzo, Tim H. Huang, Robert S. Svatek
Publikováno v:
Cancer Medicine. 12:8970-8980
Autor:
Harshit Garg, Sarah P. Psutka, Abraham Ari Hakimi, Hyung L. Kim, Ahmed M. Mansour, Deepak K. Pruthi, Michael A. Liss, Hanzhang Wang, Christine S. Gaspard, Chethan Ramamurthy, Robert S. Svatek, Dharam Kaushik
Publikováno v:
Journal of Urology. 208:542-560
Autor:
Wenjuan Cao, Junqiang Tian, Chong Li, Yanjun Gao, Xingchen Liu, Jianzhong Lu, Yuhan Wang, Zhiping Wang, Robert S. Svatek, Ronald Rodriguez
Publikováno v:
Virology Journal, Vol 14, Iss 1, Pp 1-12 (2017)
Abstract Background Conditionally replicative oncolytic adenoviruses (CRAds) display significant anti-tumor effects. However, the traditional adenovirus of serotype 5 (Ad5) entering cancer cells via coxsackie virus and adenovirus receptor (CAR) can
Externí odkaz:
https://doaj.org/article/54c5f6fc8d2241c0be1421534970c18e
Publikováno v:
Health Services and Outcomes Research Methodology. 23:185-206
Autor:
Niannian Ji, Neelam Mukherjee, Edwin E. Morales, Maggie E. Tomasini, Vincent Hurez, Tyler J. Curiel, Getahun Abate, Dan F. Hoft, Xiang-Ru Zhao, Jon Gelfond, Sourindra Maiti, Laurence J.N. Cooper, Robert S. Svatek
Publikováno v:
OncoImmunology, Vol 8, Iss 8 (2019)
Background: Intravesical bacillus Calmette-Guérin (BCG) is the gold standard immunologic agent for treating patients with high-grade non-muscle invasive bladder cancer (NMIBC). Nevertheless, relapse rates remain high and BCG unresponsive NMIBC often
Externí odkaz:
https://doaj.org/article/6d77a692e2c14502a3870a79efe0d2ef
Autor:
Joshua J. Meeks, Peter C. Black, Matthew Galsky, Petros Grivas, Noah M. Hahn, Syed A. Hussain, Matthew I. Milowsky, Gary D. Steinberg, Robert S. Svatek, Jonathan E. Rosenberg
Publikováno v:
European Urology.